{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:27:45Z","timestamp":1788226065737,"version":"build-2803163510"},"reference-count":116,"publisher":"JLE","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.nephro.2015.04.001","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T05:06:00Z","timestamp":1435035960000},"page":"213-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pathophysiologie, \u00e9pid\u00e9miologie, pr\u00e9sentation clinique, diagnostic et options th\u00e9rapeutiques dans la polykystose r\u00e9nale autosomique dominante"],"prefix":"10.1684","volume":"11","author":[{"given":"Natacha","family":"No\u00ebl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2015.04.001_bib0585","doi-asserted-by":"crossref","unstructured":"Polycystic kidney disease: the complete structure of the PKD1\u00a0gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 1995;81:289\u201398.","DOI":"10.1016\/0092-8674(95)90339-9"},{"key":"10.1016\/j.nephro.2015.04.001_bib0590","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","article-title":"PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein","volume":"272","author":"Mochizuki","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.nephro.2015.04.001_bib0595","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ncb754","article-title":"Polycystin-2\u00a0is an intracellular calcium release channel","volume":"4","author":"Koulen","year":"2002","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0600","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ndt\/gfs524","article-title":"The ciliary flow sensor and polycystic kidney disease","volume":"28","author":"Kotsis","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib0605","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0610","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0615","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1681\/ASN.2013101037","article-title":"Vasopressin-2\u00a0receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again","volume":"25","author":"Rinschen","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0620","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4161\/org.7.3.18320","article-title":"Planar cell polarity in kidney development and disease","volume":"7","author":"Carroll","year":"2011","journal-title":"Organogenesis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0625","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ydbio.2012.01.014","article-title":"A protein kinase A and Wnt-dependent network regulating an intermediate stage in epithelial tubulogenesis during kidney development","volume":"364","author":"Gallegos","year":"2012","journal-title":"Dev Biol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0630","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0635","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/MCB.01259-08","article-title":"Polycystin-1\u00a0regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1","volume":"29","author":"Distefano","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0640","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.0954-6820.1977.tb16837.x","article-title":"Fluid turnover in renal cysts","volume":"202","author":"Jacobsson","year":"1977","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.nephro.2015.04.001_bib0645","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1152\/physrev.1998.78.4.1165","article-title":"Epithelial transport in polycystic kidney disease","volume":"78","author":"Sullivan","year":"1998","journal-title":"Physiol Rev"},{"key":"10.1016\/j.nephro.2015.04.001_bib0650","doi-asserted-by":"crossref","first-page":"29181","DOI":"10.1074\/jbc.M606151200","article-title":"Laminin 5\u00a0regulates polycystic kidney cell proliferation and cyst formation","volume":"281","author":"Joly","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nephro.2015.04.001_bib0655","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cell.2009.08.045","article-title":"Polycystin-1\u00a0and -2\u00a0dosage regulates pressure sensing","volume":"139","author":"Sharif-Naeini","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.nephro.2015.04.001_bib0660","first-page":"477","article-title":"Polycystic kidney disease re-evaluated: a population-based study","volume":"79","author":"Davies","year":"1991","journal-title":"Q J Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib0665","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000045214","article-title":"Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan","volume":"80","author":"Higashihara","year":"1998","journal-title":"Nephron"},{"key":"10.1016\/j.nephro.2015.04.001_bib0670","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1523-1755.2000.00250.x","article-title":"Estimating prevalence in single-gene kidney diseases progressing to renal failure","volume":"58","author":"Levy","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0675","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","article-title":"Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany","volume":"28","author":"Neumann","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib0680","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0272-6386(83)80044-4","article-title":"Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935\u20131980","volume":"2","author":"Iglesias","year":"1983","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0685","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2215\/CJN.01581105","article-title":"Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22years","volume":"1","author":"Dicks","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0690","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1681\/ASN.V5122032","article-title":"Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease","volume":"5","author":"Ivy","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0695","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/ki.2008.397","article-title":"Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension","volume":"74","author":"Cadnapaphornchai","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0700","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0705","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.ackd.2010.01.001","article-title":"Hypertension in autosomal dominant polycystic kidney disease","volume":"17","author":"Chapman","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0710","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","article-title":"The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease","volume":"323","author":"Chapman","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib0715","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1046\/j.1523-1755.2003.00326.x","article-title":"Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease","volume":"64","author":"King","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0720","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2215\/CJN.00910306","article-title":"Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease","volume":"2","author":"Torres","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0725","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1053\/ajkd.2002.33379","article-title":"Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study","volume":"39","author":"Fick-Brosnahan","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0730","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1681\/ASN.2006080835","article-title":"Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease","volume":"17","author":"Harris","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0735","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib0740","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1681\/ASN.2013111184","article-title":"Predictors of autosomal dominant polycystic kidney disease progression","volume":"25","author":"Schrier","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0745","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1\u00a0and 2. European PKD1-PKD2\u00a0Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2015.04.001_bib0750","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2215\/CJN.01870309","article-title":"Cyst infections in patients with autosomal dominant polycystic kidney disease","volume":"4","author":"Sallee","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0755","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1016\/S0272-6386(03)00368-8","article-title":"Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease","volume":"41","author":"Bleeker-Rovers","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0760","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1093\/ndt\/gfs352","article-title":"Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities","volume":"27","author":"Jouret","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib0765","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ndt\/gfu227","article-title":"Diagnostic criteria in renal and hepatic cyst infection","volume":"30","author":"Lantinga","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib0770","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/ajkd.2000.8266","article-title":"Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease","volume":"36","author":"Grampsas","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0775","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0272-6386(88)80137-9","article-title":"The association of nephrolithiasis and autosomal dominant polycystic kidney disease","volume":"11","author":"Torres","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0780","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort","volume":"1","author":"Bae","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0785","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/jarr.2003.50005","article-title":"Cystic disease in women: clinical characteristics and medical management","volume":"10","author":"Chapman","year":"2003","journal-title":"Adv Ren Replace Ther"},{"key":"10.1016\/j.nephro.2015.04.001_bib0790","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","article-title":"Diagnosis and management of polycystic liver disease","volume":"10","author":"Gevers","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0795","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1053\/j.ajkd.2009.12.023","article-title":"Carbohydrate antigen 19-9\u00a0as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease","volume":"55","author":"Kanaan","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0800","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1665-2681(19)31406-1","article-title":"Polycystic liver disease: a clinical review","volume":"11","author":"Chandok","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0805","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ki.1994.151","article-title":"Intracranial aneurysms in autosomal dominant polycystic kidney disease","volume":"45","author":"Chauveau","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0810","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ndt\/gft437","article-title":"Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management","volume":"29","author":"Luciano","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib0815","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1681\/ASN.V131269","article-title":"Management of cerebral aneurysms in autosomal dominant polycystic kidney disease","volume":"13","author":"Pirson","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0820","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3174\/ajnr.A3437","article-title":"Should patients with autosomal dominant polycystic kidney disease be screened for cerebral aneurysms?","volume":"35","author":"Rozenfeld","year":"2014","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0825","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1681\/ASN.2008080882","article-title":"Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease","volume":"20","author":"Schrier","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0830","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM198810063191404","article-title":"Echocardiographic findings in autosomal dominant polycystic kidney disease","volume":"319","author":"Hossack","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib0835","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1053\/ajkd.2001.29216","article-title":"Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1","volume":"38","author":"Lumiaho","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0840","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/089686080502500412","article-title":"Patient characteristics associated with defects of the peritoneal cavity boundary","volume":"25","author":"Van Dijk","year":"2005","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0845","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0850","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2015.04.001_bib0855","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1\u00a0mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0860","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00467-006-0327-8","article-title":"Prognosis of autosomal dominant polycystic kidney disease diagnosed in utero or at birth","volume":"22","author":"Boyer","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0865","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.amjmed.2012.12.018","article-title":"Changing referral characteristics of patients with autosomal dominant polycystic kidney disease","volume":"126","author":"Helal","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib0870","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2215\/CJN.01460210","article-title":"Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark","volume":"5","author":"Orskov","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0875","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000046231","article-title":"Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease","volume":"21","author":"Ecder","year":"2001","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0880","doi-asserted-by":"crossref","first-page":"c18","DOI":"10.1159\/000081790","article-title":"Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease","volume":"99","author":"Nutahara","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nephro.2015.04.001_bib0885","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/01.ASN.0000018407.60002.B9","article-title":"Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study","volume":"13","author":"Schrier","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0890","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/ndt\/gfg417","article-title":"No effect of enalapril on progression in autosomal dominant polycystic kidney disease","volume":"18","author":"van Dijk","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib0895","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/ndt\/gfm731","article-title":"Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease","volume":"23","author":"Zeltner","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib0900","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1523-1755.2005.00077.x","article-title":"The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease","volume":"67","author":"Jafar","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0905","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMc1500332","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"372","author":"Schrier","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib0910","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib0915","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0920","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ackd.2009.12.006","article-title":"Management of ESRD in patients with autosomal dominant polycystic kidney disease","volume":"17","author":"Alam","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0925","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/ki.2008.352","article-title":"Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis","volume":"74","author":"Kumar","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0930","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/j.ajkd.2011.01.019","article-title":"Peritoneal dialysis as the first-line renal replacement therapy in patients with autosomal dominant polycystic kidney disease","volume":"57","author":"Li","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib0935","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5414\/CNP57208","article-title":"Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival","volume":"57","author":"Abbott","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0940","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1432-2277.2011.01237.x","article-title":"Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study","volume":"24","author":"Jacquet","year":"2011","journal-title":"Transplant Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0945","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.transproceed.2007.02.058","article-title":"Are large nonfunctional kidneys risk factors for posttransplantation urinary tract infection in patients with end-stage renal disease due to autosomal dominant polycystic kidney disease?","volume":"39","author":"Salehipour","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2015.04.001_bib0950","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1523-1755.2005.67132.x","article-title":"Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation","volume":"67","author":"de Mattos","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0955","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/ndt\/14.5.1244","article-title":"Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus","volume":"14","author":"Ducloux","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib0960","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.tp.0000248759.37146.3d","article-title":"Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation","volume":"83","author":"Hamer","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.04.001_bib0965","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.purol.2008.06.004","article-title":"[Place of nephrectomy in patients with autosomal dominant polycystic kidney disease waiting for renal transplantation]","volume":"18","author":"Cohen","year":"2008","journal-title":"Prog Urol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0970","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1464-410X.2010.09938.x","article-title":"Native nephrectomy for autosomal dominant polycystic kidney disease: before or after kidney transplantation?","volume":"108","author":"Kirkman","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0975","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneph.2014.104","article-title":"Renal transplantation in autosomal dominant polycystic kidney disease","volume":"10","author":"Kanaan","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib0980","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/TP.0b013e318246f910","article-title":"Kidney volume changes in patients with autosomal dominant polycystic kidney disease after renal transplantation","volume":"93","author":"Yamamoto","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.04.001_bib0985","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000324603","article-title":"Kidney transplant for autosomal dominant polycystic kidney disease: the superiority of concurrent bilateral nephrectomy","volume":"87","author":"Song","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib0990","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/j.1600-6143.2010.03251.x","article-title":"Embolization of polycystic kidneys as an alternative to nephrectomy before renal transplantation: a pilot study","volume":"10","author":"Cornelis","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib0995","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/TP.0b013e318191e729","article-title":"DNA testing for live kidney donors at risk for autosomal dominant polycystic kidney disease","volume":"87","author":"Huang","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2015.04.001_bib1000","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib1005","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib1010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib1015","doi-asserted-by":"crossref","first-page":"e32018","DOI":"10.1371\/journal.pone.0032018","article-title":"Cure of ADPKD by selection for spontaneous genetic repair events in Pkd1-mutated iPS cells","volume":"7","author":"Cheng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nephro.2015.04.001_bib1020","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib1025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nephro.2015.04.001_bib1030","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib1035","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2015.04.001_bib1040","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.nephro.2015.04.001_bib1045","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib1050","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","article-title":"Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study","volume":"9","author":"Braun","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib1055","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib1060","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib1065","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1681\/ASN.2012040367","article-title":"Folate-conjugated rapamycin slows progression of polycystic kidney disease","volume":"23","author":"Shillingford","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib1070","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2\u00a0receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib1075","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib1080","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib1085","doi-asserted-by":"crossref","first-page":"382","DOI":"10.7326\/0003-4819-159-6-201309170-00004","article-title":"Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease","volume":"159","author":"Erickson","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2015.04.001_bib1090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/j.ajkd.2014.01.010","article-title":"Isn\u2019t it ironic? Cost-effectiveness and willingness to pay for tolvaptan in the prevention of kidney failure in autosomal dominant polycystic kidney disease","volume":"63","author":"Nee","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib1095","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2015.04.001_bib1100","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfu093","article-title":"Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?","volume":"29","author":"Higashihara","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib1105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ndt\/gfu054","article-title":"Riding the waves: evidence for a beneficial effect of increased water intake in autosomal dominant polycystic kidney disease patients?","volume":"29","author":"Meijer","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib1110","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00163.2010","article-title":"c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation","volume":"301","author":"Elliott","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.nephro.2015.04.001_bib1115","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/ndt\/gfp777","article-title":"Triptolide reduces cyst formation in a neonatal to adult transition Pkd1\u00a0model of ADPKD","volume":"25","author":"Leuenroth","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib1120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.nephro.2015.04.001_bib1125","doi-asserted-by":"crossref","first-page":"iii5","DOI":"10.1093\/ndt\/gfu109","article-title":"The PRO PKD score, a new algorithm to predict renal outcomes in autosomal dominant polycystic kidney disease (ADPKD)","volume":"29","author":"Cornec-Le Gall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2015.04.001_bib1130","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ki.1987.290","article-title":"Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys","volume":"32","author":"Elzinga","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2015.04.001_bib1135","doi-asserted-by":"crossref","first-page":"c157","DOI":"10.1159\/000214211","article-title":"Infected hepatic and renal cysts: differential impact on outcome in autosomal dominant polycystic kidney disease","volume":"112","author":"Suwabe","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nephro.2015.04.001_bib1140","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1053\/j.ajkd.2007.04.009","article-title":"Treatment of polycystic liver disease: one size does not fit all","volume":"49","author":"Torres","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib1145","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/SLA.0b013e3181fb8dc4","article-title":"Extended liver resection for polycystic liver disease can challenge liver transplantation","volume":"252","author":"Aussilhou","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.nephro.2015.04.001_bib1150","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/j.ajkd.2007.03.018","article-title":"Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease","volume":"49","author":"Takei","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2015.04.001_bib1155","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00261-012-9931-1","article-title":"Treatment of symptomatic polycystic liver disease: transcatheter super-selective hepatic arterial embolization using a mixture of NBCA and iodized oil","volume":"38","author":"Wang","year":"2013","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.nephro.2015.04.001_bib0580","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.ajkd.2014.01.422","article-title":"Intravascular embolization therapy in patients with enlarged polycystic liver","volume":"63","author":"Hoshino","year":"2014","journal-title":"Am J Kidney Dis"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725515000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725515000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2015.04.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:12:06Z","timestamp":1741191126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725515000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":116,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1769725515000851"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2015.04.001","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiologie, \u00e9pid\u00e9miologie, pr\u00e9sentation clinique, diagnostic et options th\u00e9rapeutiques dans la polykystose r\u00e9nale autosomique dominante","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2015.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}